Report: Dendreon looking for buyer

Share this article:

Dendreon's continued slump appears to have forced its hand: Bloomberg reported Monday that the drugmaker, known for its prostate cancer med Provenge, has asked JPMorgan Chase to help it find a buyer.

Dendreon's financial forecasts have been dim: the company managed to narrow its losses during the second quarter, but said in August that it would not be able to hit its 2013 sales target, despite proof that potential patients were responding to its television ads.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.